Streetwise Reports' Article Archives — April 2018 back to current month (10)
The cell therapy space, encompassing disruptive new treatment including stem cell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late-stage development. In the first of a two-part series examining the disruptive technology, Maxim Group analyst Jason McCarthy exposes the upsides and downsides of the space, and the companies at its forefront.
Ram Selvaraju, an analyst with H.C. Wainwright & Co., relayed the most recent news concerning this firm's drug candidate.
John McCamant, editor of Medical Technology Stock Letter, reviews biotech M&A and financings, and discusses one company that is expanding its immuno-oncology pipeline.
A medicinal cannabis company has seen its Florida sales increase 253%, and the company just gained 75% control over a Massachusetts-based dispensary operation, expanding its influence in the medicinal marijuana industry.
Ram Selvaraju, an analyst with H.C. Wainwright & Co., discussed the capital raise and upcoming clinical trial data.
Douglas Loe, an analyst with Echelon Wealth Partners, made the case for why this biopharmaceutical company merits this status.
Francois Brisebois, a Laidlaw & Co. analyst, reviewed the recently released study results and upcoming catalysts.
Michael King, an analyst with JMP Securities, reported the new results that this biotech presented in March.
Francois Brisebois, an analyst with Laidlaw & Co., shared and weighed in on the latest news regarding this biopharmaceutical firm.
Biotech Delivers 'Excellent' Phase 2 Data (04/03/2018)
John McCamant, editor of Medical Technology Stock Letter, discusses a biotech with data that he views as positive from a Phase 2 LDL cholesterol lowering trial.
|"Data from DRRX's DUR-928 trial in AH showed meaningful improvements."|
|"This looks like an excellent point to buy back VIV."|
|"PMN's stock is now showing signs that it is ready to advance anew."|